Form 8-K - Current report:
SEC Accession No. 0001420720-25-000001
Filing Date
2025-01-02
Accepted
2025-01-02 07:36:39
Documents
16
Period of Report
2024-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20241230x8k.htm   iXBRL 8-K 41239
2 EX-10.1 ibio-20241230xex10d1.htm EX-10.1 263555
3 EX-99.1 ibio-20241230xex99d1.htm EX-99.1 16736
  Complete submission text file 0001420720-25-000001.txt   503239

Data Files

Seq Description Document Type Size
4 EX-101.SCH ibio-20241230.xsd EX-101.SCH 4255
5 EX-101.DEF ibio-20241230_def.xml EX-101.DEF 3992
6 EX-101.LAB ibio-20241230_lab.xml EX-101.LAB 13977
7 EX-101.PRE ibio-20241230_pre.xml EX-101.PRE 10320
19 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20241230x8k_htm.xml XML 4661
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 25500233
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)